[177Lu]Lu-DOTATATE is approved by the European Medicines Agency and the U.S. Food and Drug Administration for the treatment of SSTR2-positive gastroenteropancreatic neuroendocrine tumors based on the results of the phase III NETTER trial (6,7). This evidence concerns the gene SSTR2 and neuroendocrine neoplasm.